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This editorial introduces a special themed issue of Clinical Science on vascular causes of dementia, particularly small vessel disease, the commonest cause of vascular dementia and a central common pathway in the pathogenesis of stroke and dementia. 

The themed issue, initiated by the Vascular Experimental Theme of the Dementia Platform UK (DPUK), will include critical reviews on several key topics from experts in the field – these are in progress – but we are also keen to receive proffered reviews and original work addressing molecular and translational topics that aim to unravel the complex and multifactorial processes that contribute to development and clinical expression of human cerebral small vessel disease. It complements a Workshop, to be held in January 2017, bringing together researchers in dementia and stroke to discuss the multifactorial mechanisms contributing to neurodegeneration acting around the complex vascular-brain interface, including models, their relevance, and ways to ensure reliability. 

These are interesting times for research in stroke and dementia, and for small vessel disease(s) as central underpinning pathologies. Stroke and dementia both generate astoundingly large health and societal problems. Nearly 17 million people have a first stroke each year worldwide,[14] of whom about a third have died from the stroke by six months, a third are dependent and only a third can continue living independently. Stroke has been the second commonest cause of death in the world and the commonest cause of dependency in older adults consistently for many decades, ADDIN REFMGR.CITE [30;41] and is a common cause of cognitive decline and dementia. ADDIN REFMGR.CITE [48] Small vessel disease causes a fifth of all strokes (lacunar ischaemic stroke; many haemorrhagic strokes in older people) ADDIN REFMGR.CITE [47] and worsens outcomes after stroke.[58] There are estimated to be about 47.5million people in the world living with dementia,[45] in up to 45% of whom small vessel disease is a major contributing or the sole pathology.[5] This may be an underestimate since dementia may be under diagnosed, particularly in low and middle income countries where healthcare provision is thinly spread and family support within a familiar environment may allow failing cognition to go undetected. Many governments have now made dementia a priority for research to accelerate development of prevention and treatment, with very large research spends. 

What are the treatment options? The prevention and treatment of stroke have changed almost beyond recognition in the last 25 years, from nihilism, to becoming one of, if not the, most preventable and treatable neurological disease. Consequently, stroke incidence is falling in most developed countries, ADDIN REFMGR.CITE [12] rapid implementation of medical ADDIN REFMGR.CITE [62] and surgical treatments after transient ischaemic attack or minor stroke can reduce early recurrent stroke to negligible levels,[67] and many more patients remain independent after acute ischaemic stroke thanks to stroke units, thrombolysis and thrombectomy. ADDIN REFMGR.CITE [38;63] There is now evidence that improved stroke prevention and treatment are leading to parallel reductions in diagnoses of dementia. ADDIN REFMGR.CITE [56] 

In contrast, while several different causes of dementia are now recognised (Alzheimer’s, fronto-temporal, Lewy body, vascular), truly effective treatments for dementia have yet to emerge, and apart from possibly adopting a healthy lifestyle, ADDIN REFMGR.CITE [43] and managing modifiable vascular risk factors like hypertension (both of which are generally good ideas anyway), ADDIN REFMGR.CITE [44] little can yet be done to prevent dementia, including once early signs of cognitive impairment are evident. ADDIN REFMGR.CITE [9;59]  

Dementia research is dominated by Alzheimer’s disease which has largely focused on amyloid plaques and tau protein. However, despite decades of research, millions spent, hundreds of interventions tested (e.g. over 300 in the Tg2576 mouse model alone[10]), the lack of effective treatment or prevention has lead to calls for wider thinking about Alzheimer’s disease pathogenesis.[25] 

It has long been evident that most dementias in the elderly are mixed vascular and Alzheimer’s disease. ADDIN REFMGR.CITE [35] Human studies have shown repeatedly that the expression of cognitive impairment or dementia in life, for a given age and burden of Alzheimer’s pathology, is most strongly influenced by the amount of vascular disease rather than by the Braak stage or burden of Alzheimer’s disease pathology. ADDIN REFMGR.CITE [35;55;68] The recent finding of reductions in incidence of dementia paralleling improvements in stroke prevention and treatment, ADDIN REFMGR.CITE [34;52;56] as well as data modelling exercises, ADDIN REFMGR.CITE [23] appear to provide further evidence for important vascular contributions to dementia. 

A clear mechanistic understanding is fundamental to the development of effective interventions. In stroke, this was accelerated by the advent of neuroimaging from the late 1980s, which allowed more accurate epidemiology to differentiate haemorrhagic from ischaemic stroke, tracking of brain responses to arterial occlusion and re-opening[64] and encouraged trials of thrombolysis and thrombectomy.  Imaging with MRI and positron emission tomography (PET) also provided pathophysiological insights into stages of tissue injury in relation to blood flow in human ischaemic stroke. ADDIN REFMGR.CITE [33] A similar approach, taking advantage of the range of neuroimaging tools which are now substantially more advanced, has been set out recently for Alzheimer’s disease. ADDIN REFMGR.CITE [7] In stroke, information from neuroimaging in patients also helped balance suggestions emerging from experimental models that were simply incorrect, for example that reperfusion worsened ischaemic tissue damage after acute ischaemic stroke.[4] As we know now, reperfusion accelerates recovery[49] and is the basis of acute stroke treatment. 

In stroke, there is a long running, healthy debate on the balance of information from experimental models versus human clinical research.[53] This has helped shape awareness of the strengths and limitations of both approaches and led to improved standards for, and reliability of, experimental studies (e.g. the ARRIVE reporting guidelines, www.equator-network.org). Models of cerebral small vessel disease, subcortical ischaemic stroke and of monogenic small vessel diseases have been reviewed extensively, ADDIN REFMGR.CITE [2;28] including of vascular dementia, and the limitations. ADDIN REFMGR.CITE [24;32] These have also provided valuable confirmatory mechanistic insights that are hard to obtain in humans. 

Have dementia models received the same scrutiny? Most research into Alzheimer’s disease pathophysiology is performed in rodents but the rodent brain has proportionately much more grey and much less white matter than the human brain. As the interaction between the two is a fundamental component of human cognition, this must influence model relevance and interpretation in relation to human dementia pathologies. There has been less critical appraisal of Alzheimer’s disease models but recent work is revealing.[10] A critical appraisal of transgenic mouse models of Alzheimer’s disease identified 427 papers describing 55 transgenic models, n=11,118 animals used in 838 experiments testing 357 interventions: blinding, randomisation and sample size estimation were mostly missing, but of even more concern, the actual outcome of the intervention was described for only 16/357 interventions tested (4%).[10] Studies did not give reasons for not reporting results of the other 341/357 (96%) interventions, but the information would be important to the field. 

The wider thinking called upon to advance understanding of Alzheimer’s disease pathophysiology and treatment[25] can equally be applied to vascular dementia ADDIN REFMGR.CITE [20] and small vessel stroke. It has long been assumed that microvascular brain damage is ‘ischaemic’ and due to vessel narrowing from atheroma or spasm. ADDIN REFMGR.CITE [47] This is partly because the white matter lesions commonly seen on brain magnetic resonance scanning appear ‘white’, similar to the appearance of an acute infarct due to a large blocked artery. While narrowing of the perforating arterioles does occur, there are also areas of dilation, and occluded arterioles have rarely been found in lacunar ischaemic stroke.[3] Cerebral blood flow (CBF) falls with increasing white matter hyperintensity burden in humans, but there are no/little data to indicate a longitudinal association between low CBF and worsening WMH:[54] instead, worsening WMH leads to lower CBF. ADDIN REFMGR.CITE [60] An alternative hypothesis for SVDs suggests that the cerebral vascular endothelium – the blood brain barrier - becomes more leaky and allows plasma components (and cells) into and through the arteriolar and capillary wall, causing secondary damage in the vessel wall and surrounding tissues.[65] The process is accompanied by inflammatory cell infiltrates in the vessel wall and perivascular tissues, secondary myelin and axonal damage. This theory is now gathering momentum, ADDIN REFMGR.CITE [21;22;50;69] is supported by studies in patients ADDIN REFMGR.CITE [17;19;40] (and summarised in[66]) and experimental models, both of sporadic[1] and monogenic SVDs, ADDIN REFMGR.CITE [13] and translational genetic studies.[31]

There is still much to unravel. These topics will be addressed in this themed issue, discussed at the Workshop, and we welcome additional proffered papers describing original research and reviews:
 
-Why does the BBB become leaky? Is this primary, or just secondary to factors such as hypertension, or a bit of both? What is the role of the pericyte in modifying BBB permeability? ADDIN REFMGR.CITE [13;15] Why do some people seem to be more vulnerable to developing SVD brain damage than others – is it just genes, or do environmental and socioeconomic factors contribute? What other factors can influence development of SVD brain damage? Why do some people present with cognitive impairments while others present with stroke? 
-How does the BBB leakage influence perivascular tissues such as basement membranes, myelin and axons? ADDIN REFMGR.CITE [8] Is the myelin and axonal damage all secondary to the vessel changes, or is there an underlying vulnerability? For example, could the endothelium influence the integrity of myelin formation directly?  Might this be developmental or acquired? 
-Where does the inflammation come from? Is this primary or can systemic inflammation lead to secondary cerebral SVD? Might a similar process apply in Alzheimer’s disease,[57] where inflammation is also recognised to be an important component of the pathology? 
-What is the role of hypoperfusion and/or ischaemia – ischaemia undoubtedly occurs and must add to brain injury, but does this reflect endothelial dysfunction and vascular dysregulation[46] or is it a simpler arteriolar narrowing ‘mechanical’ process? Is the vascular dysregulation of the ageing neurovascular unit key to accumulation of Alzheimer’s pathology in the brain and failure to clear toxic waste? ADDIN REFMGR.CITE [42] How does the perivascular space regulate brain fluid and waste clearance ADDIN REFMGR.CITE [29] and what goes wrong in Alzheimer’s disease and SVD?  
-Indeed, is Alzheimer’s disease a vascular disease? Vascular risk and lifestyle factors increase the risk of Alzheimer’s disease, ADDIN REFMGR.CITE [26;27]  as well as of vascular dementia, but the correct approach to managing vascular risk in older people with failing cognition is very unclear. ADDIN REFMGR.CITE [11;51] Alzheimer’s disease is associated with altered vasoreactivity of the cerebral microvasculature, ADDIN REFMGR.CITE [6] similar to that seen in patients with overt cerebrovascular disease. ADDIN REFMGR.CITE [39] If so, efforts to improve function of microvessels might delay or even prevent clinical expression of Alzheimer’s dementia.
-More practically, is there a relevant animal model of mixed dementia? ADDIN REFMGR.CITE [16] Do current models reflect mechanisms that are known to be related to vascular disease or dementia in humans? Where the model does not use a mechanism that reflects common pathogenesis in humans, but nonetheless appears to cause at least some aspects of the human pathology,[18] is that telling us something useful about multiple disease pathways that is worthy of exploitation?  
-Are humanized models such as iPSCs useful in probing molecular mechanisms relevant to SVD? Can they realistically recapitulate the neuron-glial-vascular interface and interactions? If so will it be feasible to define the important molecules that underlie disruption of cellular interactions in SVD as drug targets and use  hIPSCs in drug screening?


Considering that a broad consensus may be emerging in the dementia field, and recognising that multifactorial or mixed dementias are likely more common than pure dementia of any type, it may be more valuable to describe an individual’s mixed dementia in terms of the proportion due to Alzheimer’s or vascular pathology, ADDIN REFMGR.CITE [61] because in turn this may assist in determining patient treatment and management.  It may be a more realistic reflection of the messy world of multiple concurrent pathologies that accumulate in later life. In which case, the science of clinical research and laboratory methods, particularly the experimental models, need to reflect this reality.   
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